Exelixis patent win sets MSN generic to 2030
Rhea-AI Filing Summary
EXELIXIS, INC. (EXEL) reports a favorable appellate ruling in its cabozantinib patent litigation against MSN Laboratories. On August 31, 2026, the U.S. Court of Appeals for the Federal Circuit affirmed a Delaware district court judgment that U.S. Patent Nos. 11,091,439, 11,091,440 and 11,098,015 are not invalid and dismissed as moot MSN’s appeal regarding U.S. Patent No. 11,298,349, which expires on February 10, 2032.
Based on the ruling, the effective date of any final FDA approval of MSN’s ANDA for its proposed generic product may not be earlier than January 15, 2030, the expiration date of the three affirmed patents, subject to further appeals, regulatory exclusivity, and separate litigation over U.S. Patent No. 12,128,039, which expires in February 2032 and has a trial scheduled to begin in November 2026.
Positive
- Federal Circuit affirms key patents, supporting U.S. Patent Nos. 11,091,439, 11,091,440 and 11,098,015 and limiting generic entry timing.
- Generic approval date pushed to at least January 15, 2030 for MSN’s ANDA, extending protection for Exelixis’ product, subject to further proceedings and other litigation.
Negative
- Ongoing patent litigation risk remains around U.S. Patent No. 12,128,039, expiring February 2032, with trial scheduled for November 2026, which could affect longer-term exclusivity.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Earliest MSN ANDA final FDA approval date: January 15, 2030
Expiration date of U.S. Patent No. 11,091,439: January 15, 2030
Expiration date of U.S. Patent No. 11,091,440: January 15, 2030
+4 more
7 metrics
Earliest MSN ANDA final FDA approval date
January 15, 2030
Effective date for any final FDA approval of MSN’s ANDA, based on the Court of Appeals’ opinion
Expiration date of U.S. Patent No. 11,091,439
January 15, 2030
Patent expiration date tied to limiting MSN’s ANDA approval timing
Expiration date of U.S. Patent No. 11,091,440
January 15, 2030
Patent expiration date tied to limiting MSN’s ANDA approval timing
Expiration date of U.S. Patent No. 11,098,015
January 15, 2030
Patent expiration date tied to limiting MSN’s ANDA approval timing
Expiration date of U.S. Patent No. 11,298,349
February 10, 2032
Patent addressed in appeal dismissed as moot
Expiration of U.S. Patent No. 12,128,039
February 2032
Subject of separate litigation with trial scheduled for November 2026
Trial start for litigation over U.S. Patent No. 12,128,039
November 2026
Scheduled trial date in separate litigation concerning generic competition
Key Terms
Abbreviated New Drug Application (ANDA), regulatory exclusivity, forward-looking statements, U.S. Court of Appeals for the Federal Circuit, +1 more
5 terms
Abbreviated New Drug Application (ANDA) regulatory
"final approval by the U.S. Food and Drug Administration of MSN’s ANDA shall not be"
An Abbreviated New Drug Application (ANDA) is the regulatory request a company files to get approval to market a generic version of an existing prescription drug by showing it has the same active ingredient, strength, dosage form and works the same in the body without repeating full clinical trials. Think of it as proving your copy of a recipe tastes and performs the same as the original. For investors, ANDA approvals determine whether a lower‑cost competitor can enter a market, affecting sales, pricing, patent disputes and the value of both the original drug maker and the generic entrant.
regulatory exclusivity regulatory
"subject to any further appellate proceedings, applicable regulatory exclusivity, and the outcome"
A period during which regulators prevent competitors from relying on a drug or device maker’s safety and effectiveness data to win approval for their own rival product, creating a temporary market shield beyond or instead of a patent. For investors, this delay in direct competition can extend a product’s revenue runway and improve predictable cash flow, like giving a seller exclusive access to a popular storefront for a set time before others can move in.
forward-looking statements regulatory
"contains forward-looking statements, including, without limitation, statements related to the timing"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
U.S. Court of Appeals for the Federal Circuit regulatory
"announced that the U.S. Court of Appeals for the Federal Circuit issued a decision"
A U.S. Court of Appeals for the Federal Circuit is a national federal appeals court that reviews legal disputes in specialized areas such as patents, government contracts, and certain trade and regulatory matters. Its rulings act like a referee’s call that sets the rules for many companies at once, and can change how protected a product is, whether a contract stands, or how regulators must act—outcomes that often move investor expectations and company valuations.
Risk Factors regulatory
"including the factors described under the caption "Risk Factors" in Exelixis' most recent"
Risk factors are elements or conditions that could cause an investment's value to decrease or lead to potential losses. They are like warning signs or obstacles that can affect the success of an investment, making it uncertain or more unpredictable. Recognizing risk factors helps investors understand the possible challenges and make more informed decisions.
FAQ
What did EXEL (Exelixis, Inc.) announce regarding its patent litigation with MSN?
Exelixis announced that the U.S. Court of Appeals for the Federal Circuit affirmed a Delaware district court judgment that U.S. Patent Nos. 11,091,439, 11,091,440 and 11,098,015 are not invalid, in the case against MSN Laboratories Private Limited et al.
How does the ruling affect potential generic entry for Exelixis (EXEL)?
Based on the opinion, any final FDA approval of MSN’s ANDA shall not be earlier than January 15, 2030, the expiration date of U.S. Patent Nos. 11,091,439, 11,091,440 and 11,098,015, subject to further appellate proceedings and other factors.
What happened to U.S. Patent No. 11,298,349 in the EXEL case?
The Court of Appeals dismissed as moot MSN’s appeal relating to the validity of U.S. Patent No. 11,298,349, which expires on February 10, 2032, and vacated the portion of the district court’s decision addressing that patent.
Which future litigation could still impact Exelixis (EXEL) exclusivity?
Separate litigation involves U.S. Patent No. 12,128,039, which expires in February 2032. Trial in that case is currently scheduled to begin in November 2026, and its outcome could affect exclusivity duration.
Does Exelixis (EXEL) include forward-looking statements in this disclosure?
Yes. Exelixis includes forward-looking statements about the timing of any MSN generic launch, litigation outcomes, and regulatory exclusivity, and notes that actual results may differ due to risks described in its Form 10-K, Form 10-Q, and other SEC filings.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
| FORM | |||||
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 31, 2026
 | ||
| (Exact name of registrant as specified in its charter) | ||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of principal executive offices) (Zip Code)
(650 ) 837-7000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On August 31, 2026, Exelixis, inc. (Exelixis) announced that the U.S. Court of Appeals for the Federal Circuit (Court of Appeals) issued a decision in Exelixis, Inc. v. MSN Laboratories Private Limited et al., Appeal No. 25-1236, affirming the judgment of the U.S. District Court for the District of Delaware that U.S. Patent Nos. 11,091,439, 11,091,440 and 11,098,015 are not invalid.
The Court of Appeals also dismissed as moot MSN’s appeal relating to the validity of U.S. Patent No. 11,298,349, which expires on February 10, 2032, and vacated the portion of the district court’s decision addressing that issue.
Based on the Court of Appeals’ opinion, the effective date of any final approval by the U.S. Food and Drug Administration of MSN’s ANDA shall not be a date earlier than January 15, 2030, the expiration date of each of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015, subject to any further appellate proceedings, applicable regulatory exclusivity, and the outcome of separate litigation involving U.S. Patent No. 12,128,039, which expires in February 2032 and for which trial is currently scheduled to begin in November 2026.
This Current Report on Form 8-K contains forward-looking statements, including, without limitation, statements related to the timing of any commercial launch by MSN of its proposed generic product in the U.S., the outcome of pending litigation, and applicable regulatory exclusivity. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, including the factors described under the caption "Risk Factors" in Exelixis' most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis' other filings with the Securities and Exchange Commission. Exelixis undertakes no obligation to update these forward-looking statements except as required by law.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EXELIXIS, INC. | |||||||||||
| August 31, 2026 | /s/ Brenda J. Hefti | ||||||||||
| Date | Brenda J. Hefti | ||||||||||
| Senior Vice President and General Counsel | |||||||||||